Exelixis Inc Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value
Exelixis Inc (EXEL) had Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value of $154.36 million as of 2017-12-29, per its 10-K filed 2018-02-26.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue · last filed 2018-02-26
- 2017-12-29: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $154.36M.
- 2017-09-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $134.90M.
- 2017-06-30: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $133.20M.
- 2017-03-31: Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value $184.40M.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than Twelve Months, Fair Value |
|---|---|
| 2017-12-29 | $154.36M 10-K · filed 2018-02-26 |
| 2017-09-30 | $134.90M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $133.20M 10-Q · filed 2017-08-02 |
| 2017-03-31 | $184.40M 10-Q · filed 2017-05-01 |
| 2016-12-31 | $172.10M 10-K · filed 2017-02-27 |
| 2016-12-30 | $169.21M 10-K · filed 2018-02-26 |
| 2016-09-30 | $67.30M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $13.10M 10-Q · filed 2016-08-03 |
| 2016-03-31 | $37.90M 10-Q · filed 2016-05-04 |
| 2015-12-31 | $109.50M 10-K · filed 2016-02-29 |
| 2015-09-30 | $27.90M 10-Q · filed 2015-11-10 |
| 2015-06-30 | $43.40M 10-Q · filed 2015-08-11 |
| 2015-03-31 | $103.30M 10-Q · filed 2015-04-30 |
| 2014-12-31 | $82.80M 10-K · filed 2015-03-02 |
| 2014-09-30 | $64.60M 10-Q · filed 2014-11-04 |
| 2014-06-30 | $50.10M 10-Q · filed 2014-07-31 |
| 2014-03-31 | $39.50M 10-Q · filed 2014-05-01 |
| 2013-12-31 | $65.30M 10-K · filed 2014-02-20 |
| 2013-09-30 | $106.80M 10-Q · filed 2013-10-30 |
| 2013-06-30 | $223.30M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $174.00M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $196.10M 10-K · filed 2013-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |